Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | STS | P08842 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | NAAA | Q02083 | 2/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.33 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.33 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26276749 | 0.98 | CYP2C19 (0.44) | CYP2C19EPHX1STSCA1CA2 | |
| Hydrochloric Acid SCHEMBL28854896 | 0.96 | CYP2C19 (0.43) | CYP2C19EPHX1STSCA1CA2 | |
| SCHEMBL181447 | 0.96 | CYP2C19 (0.46) | CYP2C19EPHX1STSCA1CA2 | |
| SCHEMBL3781529 | 0.94 | CYP2C19 (0.49) | CYP2C19EPHX1STSCA1CA2 | |
| SCHEMBL2706509 | 0.94 | CYP2C19 (0.43) | CYP2C19EPHX1STSCA1CA2 | |
| SCHEMBL10072546 | 0.85 | CYP2C19 (0.38) | CYP2C19EPHX1CA1CA2CA12 | |
| SCHEMBL9895770 | 0.78 | CYP2D6 (0.44) | CYP2C19STS | |
| SCHEMBL16086274 | 0.77 | CYP2C19 (0.47) | CYP2C19EPHX1CA1CA2CA12 | |
| SCHEMBL16086282 | 0.74 | CYP2C19 (0.48) | CYP2C19EPHX1CA1CA2CA12 | |
| SCHEMBL1433032 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2864318-B1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1R KINASE INHIBITORS | MACROPHAGE PHARMA LTD (GB) | 2017-08-09 | — | — | EP | disclosed |
| EP-2864318-B1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1R KINASE INHIBITORS | MACROPHAGE PHARMA LTD (GB) | 2017-08-09 | — | — | EP | disclosed |
| US-20170157118-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | MACROPHAGE PHARMA LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-20170157118-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | MACROPHAGE PHARMA LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-20170157118-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | MACROPHAGE PHARMA LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-9604940-B2 | 2-aminopyrazine derivatives as CSF-1R kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2017-03-28 | — | — | US | disclosed |
| US-9604940-B2 | 2-aminopyrazine derivatives as CSF-1R kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2017-03-28 | — | — | US | disclosed |
| US-9604940-B2 | 2-aminopyrazine derivatives as CSF-1R kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2017-03-28 | — | — | US | disclosed |
| US-20150368210-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2015-12-24 | — | — | US | disclosed |
| US-20150368210-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2015-12-24 | — | — | US | disclosed |
| US-20140155439-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140155439-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-05 | — | — | US | disclosed |
| WO-2014001802-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2014-01-03 | — | — | WO | disclosed |
| WO-2014001802-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2014-01-03 | — | — | WO | disclosed |
| US-20130303576-A1 | ENZYME INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-11-14 | — | — | US | disclosed |
| US-20130303576-A1 | ENZYME INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-11-14 | — | — | US | disclosed |
| US-20120149736-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2012-06-14 | — | — | US | disclosed |
| US-20120149736-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2012-06-14 | — | — | US | disclosed |
| WO-2012025701-A1 | ALPHA, ALPHA - DI SUBSTITUTED GLYCINE ESTER DERIVATIVES AND THEIR USE AS HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2012-03-01 | — | — | WO | disclosed |
| WO-2010097586-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303576-A1 | ENZYME INHIBITORS | HDAC1, HDAC4, HDAC3 | CYP2C19 1581/4885EPHX1 887/4885STS 418/4885 |
| US-20140155439-A1 | ENZYME INHIBITORS | HDAC4, HDAC1, HDAC3 | CYP2C19 2170/4885EPHX1 1882/4885STS 1450/4885 |
| US-20170157118-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CSF1R, CSF3R, FLT3 | CYP2C19 4186/4885EPHX1 3047/4885STS 3026/4885 |
| US-20120149736-A1 | ENZYME INHIBITORS | HAT1, HDAC1, NAT1 | CYP2C19 1917/4885EPHX1 982/4885STS 390/4885 |
| US-20150368210-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CSF1R, CSF3R, FLT3 | CYP2C19 4186/4885EPHX1 3047/4885STS 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.